Compare Stocks → Man Who Called Nvidia at $1.10 Says Buy This Now... (From The Oxford Club) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:BJDXNASDAQ:MOTSNASDAQ:NVIVNASDAQ:SINT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$0.50+16.3%$0.57$0.39▼$13.98$1.35M1.06168,397 shs2.17 million shsMOTSMotus GI$0.08-27.7%$0.16$0.05▼$14.25$610K1.83156,382 shs1.05 million shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shsSINTSintx Technologies$4.55-11.7%$9.37$4.12▼$364.00$2.78M1.34213,516 shs155,731 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+15.50%-16.65%-0.40%-38.87%-88.12%MOTSMotus GI-25.33%-49.68%+11.21%-87.92%-99.30%NVIVInVivo Therapeutics0.00%0.00%0.00%0.00%-75.31%SINTSintx Technologies-11.65%-30.11%-42.98%-81.92%-98.60%Top 5 Tech Stocks to Buy for 2024 (Ad)The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024",MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBJDXBluejay DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics2.00HoldN/AN/AMOTSMotus GI3.00Buy$28.8836,730.36% UpsideNVIVInVivo TherapeuticsN/AN/AN/AN/ASINTSintx Technologies2.00HoldN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay Diagnostics$250K5.38N/AN/A$2.34 per share0.21MOTSMotus GI$320K1.41N/AN/A$1.74 per share0.05NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/ASINTSintx Technologies$2.63M1.06N/AN/A$329.74 per share0.01Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$9.95M-$9.01N/A∞N/AN/A-218.30%-146.12%6/12/2024 (Estimated)MOTSMotus GI-$12.87M-$15.64N/A∞N/A-3,239.75%-1,731.08%-115.99%N/ANVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ASINTSintx Technologies-$8.26M-$358.00N/A∞N/A-318.99%-81.96%-52.43%8/13/2024 (Estimated)Latest SINT, BJDX, MOTS, and NVIV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024MOTSMotus GIN/A-$0.88-$0.88-$0.88N/A$0.06 million5/13/2024Q1 2024SINTSintx TechnologiesN/A-$22.00-$22.00-$22.00N/A$0.69 million3/28/2024Q4 2023BJDXBluejay Diagnostics-$0.68-$1.78-$1.10-$1.78N/AN/A3/27/2024Q4 2023SINTSintx TechnologiesN/A-$18.00-$18.00-$0.09N/A$0.90 million3/18/2024Q4 2023MOTSMotus GIN/A-$4.13-$4.13-$3.78N/A$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ASINTSintx TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A2.262.26MOTSMotus GI0.221.741.67NVIVInVivo TherapeuticsN/A14.3014.30SINTSintx TechnologiesN/A1.841.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%MOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%SINTSintx Technologies18.38%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics17.60%MOTSMotus GI1.57%NVIVInVivo Therapeutics2.45%SINTSintx Technologies0.79%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics102.69 million2.22 millionNot OptionableMOTSMotus GI155.77 million5.68 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableSINTSintx Technologies43610,000608,000Not OptionableSINT, BJDX, MOTS, and NVIV HeadlinesRecent News About These CompaniesJune 6, 2024 | globenewswire.comSINTX Technologies Receives Additional SBIR Contract for 3D Printing TechnologyMay 29, 2024 | marketbeat.comSintx Technologies (NASDAQ:SINT) Trading Down 8.5%May 29, 2024 | finance.yahoo.comSINTX TECHNOLOGIES SIGNS AGREEMENT TO ENTER KOREAN TECHNICAL CERAMICS SECTORMay 28, 2024 | marketbeat.comShort Interest in Sintx Technologies, Inc. (NASDAQ:SINT) Decreases By 78.8%May 28, 2024 | marketwatch.comSiNtx Technologies Down 39% After Reverse SplitMay 24, 2024 | msn.comWhy SINTX Technologies Stock Is FallingMay 23, 2024 | globenewswire.comSINTX TECHNOLOGIES ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE MAY 28, 2024May 17, 2024 | uk.finance.yahoo.comSintx Technologies, Inc. (0A8S.L)May 15, 2024 | bovnews.comSINTX Technologies Inc (SINT) Stock is poised for a successful quarterMay 15, 2024 | msn.comWhy SiNtx Technologies Stock Is SoaringMay 15, 2024 | msn.comWhy Is Sintx Technologies (SINT) Stock Up 113% Today?May 14, 2024 | msn.comSINT Stock Earnings: SINTX Technologies Misses EPS, Misses Revenue for Q1 2024April 30, 2024 | tctmagazine.comProdways & SINTX announce deep technical ceramic 3D printing partnershipApril 29, 2024 | msn.comWhy SINTX Technologies Shares Are SkyrocketingApril 29, 2024 | globenewswire.comSINTX AND PRODWAYS AGREE ON CERAMIC SLURRY SUPPLY AND 3D PRINTING AGREEMENTApril 3, 2024 | msn.comWhy SINTX Technologies Stock Is Getting HammeredApril 3, 2024 | globenewswire.comSINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common StockApril 1, 2024 | msn.comWhy SINTX Technologies Stock Hit A New All-Time Low TodayMarch 30, 2024 | itnewsonline.comDDC Appoints Vice President to Drive Operational ExcellenceMarch 29, 2024 | globenewswire.comSINTX Technologies Announces Proposed Public Offering of Common StockMarch 28, 2024 | investorplace.comSINT Stock Earnings: SINTX Technologies Beats EPS, Beats Revenue for Q4 2023New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBluejay DiagnosticsNASDAQ:BJDXBluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.Sintx TechnologiesNASDAQ:SINTSintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.